Anebulo’s Selonabant Phase 1 Completion: What Investors Should Watch Next

Anebulo Pharmaceuticals, Inc. (ANEB) announced an update on their ongoing clinical study.

Anebulo Pharmaceuticals, Inc. is running a Phase 1 study called “A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Selonabant in Healthy Adult Subjects Aged 18 to 30 Years.” It aims to check early safety and how the drug moves in the body, a key step before testing in patients.

The study tests an intravenous drug called selonabant, also known as ANEB-001. It is designed to be given through a short infusion and is intended to support future use in treating conditions linked to drug exposure or related nervous system effects.

This is an interventional trial where volunteers are randomly assigned to receive either selonabant or a look‑alike placebo. The study is double‑blind with four groups masked, and it uses a single ascending dose approach so each new group gets a higher dose once safety is confirmed.

The trial uses a sequential design, so cohorts receive doses in order from low to high. The primary goal is treatment‑focused, meaning the company is gathering data needed to move toward use in real‑world care rather than just exploring biology.

The study was first submitted on September 29, 2025, marking the formal start of the clinical plan. The latest update was filed on May 6, 2026, showing that data entry is current and that the sponsor is actively maintaining regulatory records.

The overall status is listed as completed, which means dosing and follow‑up for this Phase 1 stage are finished. Primary completion and full completion dates will guide when investors can expect top‑line safety and drug‑level data to be shared publicly.

For investors, a clean safety readout from this trial could support a higher valuation for ANEB by lowering early development risk. Any hint of tolerability issues or unclear drug exposure could pressure the stock, as the company’s pipeline is still early and highly sensitive to single‑asset news.

The collaboration with the National Institute on Drug Abuse (NIDA) adds some validation and may help sentiment by signaling external interest in the program. However, investors should note that many early‑stage CNS and addiction‑related programs fail, so near‑term moves in ANEB shares may be driven more by expectations than by immediate revenue impact.

Competitive pressure in central nervous system and substance‑related therapies is rising, but few companies have strong, late‑stage assets targeting the same niche as selonabant. This Phase 1 update mainly shifts risk perception rather than market share, so traders may focus on how quickly Anebulo can advance to patient trials compared with peers.

The selonabant Phase 1 study has been completed and recently updated, and further operational and scientific details remain available on the ClinicalTrials portal.

To learn more about ANEB’s potential, visit the Anebulo Pharmaceuticals, Inc. drug pipeline page.